Azushima Kengo, Tamura Kouichi, Wakui Hiromichi, Maeda Akinobu, Kanaoka Tomohiko, Ohsawa Masato, Haku Sona, Uneda Kazushi, Toya Yoshiyuki, Umemura Satoshi
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Intern Med. 2012;51(24):3387-9. doi: 10.2169/internalmedicine.51.8567. Epub 2012 Dec 15.
We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.
我们在此报告首例由阿利吉仑引起的显著高甘油三酯血症病例。一名患有慢性肾脏病的42岁男性，服用抗高血压药物约10年，因高血压控制不佳，开始接受阿利吉仑治疗，剂量为每日150毫克。六周后，尽管患者血压下降，但实验室检查显示显著高甘油三酯血症和肌酐水平升高。我们怀疑发生了阿利吉仑的不良事件，遂停用该药物。此后，高甘油三酯血症和升高的肌酐水平自行改善。在患者的临床病程中出现了短暂性嗜酸性粒细胞增多以及药物淋巴细胞刺激试验（DLST）对阿利吉仑的强阳性反应，我们确定显著高甘油三酯血症为阿利吉仑的不良事件。
